OWPC SEC Filings - One World Products, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1622244

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to One World Products, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

August 14, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period
July 15, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 15, 2025 (July 11, 2025) Date of Report (Date of earliest event reported) One World Products, Inc. (Exact name of registrant as specified in its charter) Nevada 000-56151 61-1744826 (State or other jurisdiction of incorporation)
July 15, 2025	EX-10.1	ASSET PURCHASE AGREEMENT Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the “Agreement”) is made and entered into as of July 11, 2025, by and among EBPIE, Inc., a Michigan limited liability company (“Buyer”), One World Products, Inc., a Nevada corporation (“Parent”), and Eco Bio Plastics Midland, Inc., a Delaware corporation (“Seller”). RECITALS WHEREAS, the parent company of Seller, Institute of Com
July 15, 2025	EX-10.2	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into on July 11, 2025 (the “Effective Date”), by and between EBPIE, LLC, a Michigan limited liability company (the “Company”), and Fukuji Saotome (the “Executive”). WHEREAS, the Company desires that the Executive serve as Chief Operating Officer of the Company; and WHEREAS, the Company and
July 15, 2025	EX-10.3	One World Pharma, Inc. Stock Option Grant Notice (2019 Stock Incentive Plan) Exhibit 10.3 One World Pharma, Inc. Stock Option Grant Notice (2019 Stock Incentive Plan) One World Pharma, Inc. (the “Company”), pursuant to its 2019 Stock Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth herein and in the Optio
July 15, 2025	EX-99.1	One World Products Acquires Eco Bio Plastics, Advancing U.S. Manufacturing and Sustainable Packaging Innovation Exhibit 99.1 One World Products Acquires Eco Bio Plastics, Advancing U.S. Manufacturing and Sustainable Packaging Innovation LAS VEGAS, NV - July 15, 2025 (NEWMEDIAWIRE) - One World Products, Inc. (“OWP” or the “Company”) (OTCQB: OWPC), a publicly-traded sustainability innovator led by Chairman and CEO Isiah Thomas, today announced the acquisition of Eco Bio Plastics Midland, Inc. (“Eco Bio” or “E
June 30, 2025	EX-10.1	CFO Consulting Agreement dated June 20, 2025, between the Company and William (Bill) Rowland, d/b/a W.P. Rowland Properties Corp. Exhibit 10.1 CFO CONSULTING AGREEMENT CFO CONSULTING AGREEMENT dated as of June 20, 2025 (this “Agreement”), between One World Products, Inc., a Nevada corporation (the “Company”), and Bill Rowland, DBA: W.P. Rowland Properties Corp (the “Consultant”). WHEREAS, the Company desires to engage Consultant to provide consulting services, upon the terms and subject to the conditions hereinafter set fort
June 30, 2025	8-K	Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2025 (May 7, 2025) Date of Report (Date of earliest event reported) One World Products, Inc. (Exact name of registrant as specified in its charter) Nevada 000-56151 61-1744826 (State or other jurisdiction of incorporation) (
June 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS,
June 10, 2025	EX-10.1	Letter of Intent between the Company and Eco Bio Plastics Midland, Inc. Exhibit 10.1 ONE WORLD PRODUCTS, INC. 6605 Grand Montecito Parkway, Suite 100 Las Vegas, Nevada 89149 June 4, 2025 Eco Bio Plastics Midland, Inc. Letter of Intent Gentlemen: This Letter of Intent summarizes certain terms under which our company, One World Products, Inc. (“OWPC”) would acquire substantially all of the assets (collectively, the “Assets”) from your company, Eco Bio Plastics Midland,
June 10, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 10, 2025 (June 4, 2025) Date of Report (Date of earliest event reported) One World Products, Inc. (Exact name of registrant as specified in its charter) Nevada 000-56151 61-1744826 (State or other jurisdiction of incorporation)
June 3, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS, INC.
April 1, 2025	NT 10-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response.......... 2.50 SEC FILE NUMBER 000-56151 CUSIP NUMBER 68248W 108 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: Dec
November 14, 2024	EX-10.16	Exchange Agreement, dated November 8, 2014, between One World Products, Inc. and Isiah L. Thomas, III (incorporated by reference to exhibit 10.16 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission by One World Products, Inc. on November 14, 2024) Exhibit 10.16 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of November 8, 2024, by and between One World Products, Inc., a Nevada corporation (the “Company”), and Isiah L. Thomas, III (the “Thomas”) (the Company and Thomas are referred to as the “Parties”). RECITALS WHEREAS, during the several months preceding the date of this Agreement, the management personnel
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUC
November 14, 2024	EX-3.7	Certificate of Designation of Series C Preferred Stock of the Company, dated October 10, 2024 (incorporated by reference to exhibit 3.7 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission by One World Products, Inc. on November 14, 2024) Exhibit 3.7
August 21, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS, I
August 15, 2024	NT 10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response.......... 2.50 SEC FILE NUMBER 000-56151 CUSIP NUMBER 68248W 108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: Jun
July 5, 2024	EX-10.1	Employment, Confidentiality and Proprietary Rights Agreement, dated July 1, 2024, between the Company and Todd Peterson (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 5, 2024) Exhibit 10.1 EMPLOYMENT, CONFIDENTIALITY AND PROPRIETARY RIGHTS AGREEMENT This Employment, Confidentiality and Proprietary Rights Agreement (“Agreement”) is entered into as of the 1st day of July, 2024 (the “Effective Date”) by and between One World Products, Inc. (the “Company”), and Todd Peterson (the “Employee”). WHEREAS, the Company desires to employ the Employee as the Chief Financial Officer
July 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 1, 2024 Date of Report (Date of earliest event reported) One World Products, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 1, 2024 Date of Report (Date of earliest event reported) One World Products, Inc. (Exact name of registrant as specified in its charter) Nevada 000-56151 61-1744826 (State or other jurisdiction of incorporation) (Commission File
June 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS,
May 23, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS, INC.
May 17, 2024	NT 10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response.......... 2.50 SEC FILE NUMBER 000-56151 CUSIP NUMBER 68248W 108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: Mar
April 25, 2024	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 19, 2024 Date of Report (Date of earliest event reported) One World Products, Inc. (Exact name of registrant as specified in its charter) Nevada 000-56151 61-1744826 (State or other jurisdiction of incorporation) (Commission Fi
April 1, 2024	NT 10-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response.......... 2.50 SEC FILE NUMBER 000-56151 CUSIP NUMBER 68248W 108 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: Dec
February 29, 2024	424B3	21,366,700 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276662 21,366,700 Shares of Common Stock This prospectus relates to the resale of up to 21,366,700 shares of common stock of One World Products, Inc., a Nevada corporation, which may be resold by Tysadco Partners, LLC (which we refer to as Tysadco or the selling stockholder), consisting of up to 20,000,000 shares of common stock issuable pursua
February 6, 2024	CORRESP	One World Products, Inc. One World Products, Inc. 6605 Grand Montecito Pkwy, Suite 100 Las Vegas, Nevada 89149 (952) 405-6216 February 6, 2024 Securities and Exchange Commission 100 F Street, NE Washington, D.C., 20549 Attn: Re: One World Products, Inc. (CIK No. 0001622244) Registration Statement on Form S-1, as amended (File No. 333-276662) Dear Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C (“Rule 461”) prom
February 5, 2024	EX-10.23	Offer Letter dated February 14, 2022 by and between the Company and Timothy Woods Exhibit 10.23 One World Products, Inc. 3471 W. Oquendo Road, Suite 301 Las Vegas, NV 89118 February 14, 2022 Timothy Woods 8191 Quinn Terrace Vienna, VA 22180 Dear Mr. Woods: We are pleased to confirm the terms of your employment with One World Products, Inc. (the “Company”), effective February 14, 2022 (the “Effective Date”). The details of your employment are as follows: Title; Duties: You will
February 5, 2024	S-1/A	As filed with the Securities and Exchange Commission on February 5, 2024 As filed with the Securities and Exchange Commission on February 5, 2024 Registration No.
January 23, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 FILING FEES CALCULATION OF REGISTRATION FEE Title of each class of Securities to be registered Amount to be registered(1) Proposed maximum offering price per share(2) Proposed maximum aggregate offering price(2) Amount of registration fee(3) Common stock, no par value per share 21,366,700 $ 0.
January 23, 2024	S-1	As filed with the Securities and Exchange Commission on January 23, 2024 As filed with the Securities and Exchange Commission on January 23, 2024 Registration No.
January 19, 2024	SC 13D	OWPC / One World Products, Inc. / McCabe John S Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ONE WORLD PRODUCTS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68248W108 (CUSIP Number) John McCabe 160 Kincaid Lane Boyce, LA 71409 With copy to: Alison Newman, Esq. Fox Rothschild LLP 101 Park Avenue, 17
January 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 One World Produ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 One World Products, Inc. (Exact name of registrant as specified in charter) Nevada 000-56151 61-1744826 (State or other Jurisdiction of Incorporation) (Commission Fi
November 15, 2023	NT 10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response.......... 2.50 SEC FILE NUMBER 000-56151 CUSIP NUMBER 68248W 108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: Sep
November 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUC
August 28, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS, I
August 15, 2023	NT 10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response.......... 2.50 SEC FILE NUMBER 000-56151 CUSIP NUMBER 68248W 108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: Jun
July 31, 2023	RW	One World Products, Inc. 6605 Grand Montecito Pkwy, Suite 100, Las Vegas, Nevada 89149 July 31, 2023 One World Products, Inc. 6605 Grand Montecito Pkwy, Suite 100, Las Vegas, Nevada 89149 July 31, 2023 Via Edgar Mr. Tyler Howes Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: One World Products, Inc. Request for Withdrawal of Registration Statement on Form S-1 Filed October 4, 2022 File No. 333-267734 Dear Mr. Howes: Pursuant to R
July 5, 2023	EX-10.5	Securities Purchase Agreement, dated as of June 23, 2023, between the Company and AJB Capital Investments LLC (incorporated by reference to Exhibit 10.5 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 5, 2023) Exhibit 10.5 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 23, 2023, by and between ONE WORLD PRODUCTS, INC., a Nevada corporation, with headquarters located at 6605 Grand Montecito Pkwy., Suite 100, Las Vegas, NV 89149 (the “Company”), and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company, with its address at 4700 Sheridan St
July 5, 2023	EX-10.7	Registration Rights Agreement, dated June 23, 2023, between the Company and AJB Capital Investments LLC (incorporated by reference to Exhibit 10.7 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 5, 2023) Exhibit 10.7 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”), dated as of June 23, 2023, by and between ONE WORLD PRODUCTS, INC., a Nevada corporation, with headquarters located at 6605 Grand Montecito Pkwy., Suite 100, Las Vegas, NV 89149 (the “Company”), and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company, with offices at 4700 Sheridan Street
July 5, 2023	EX-4.1	Promissory Note of the Company in the Principal Amount of $300,000 issued to AJB Capital Investments LLC, dated June 23, 2023 (incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 5, 2023) Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T
July 5, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS,
June 1, 2023	EX-10.1	Offer Letter dated April 25, 2003 by and between the Company and Jeorg Sommer (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2023) Exhibit 10.1
June 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 One World Products, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 One World Products, Inc. (Exact name of registrant as specified in charter) Nevada 000-56151 61-1744826 (State or other Jurisdiction of Incorporation or Organization) (Co
May 16, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires:April 30, 2025 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-56151 CUSIP NUMBER 68248W 108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023
May 15, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS, INC.
May 15, 2023	EX-21.1	Subsidiaries EXHIBIT 21.1 Subsidiaries State/Country of Subsidiary Incorporation OWP Ventures, Inc.(1) Delaware One World Pharma, S.A.S.(2) Bogotá Colombia Colombian Hope, S.A.S.(2) Bogotá Colombia Agrobase, S.A.S.(2) Bogotá Colombia (1)Wholly-owned subsidiary of One World Pharma, Inc. subsequent to merger on February 21, 2019 (2)Wholly-owned subsidiary of OWP Ventures, Inc.
April 3, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires:April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-200529 CUSIP NUMBER 68248W 108 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December
November 14, 2022	EX-10.16	Convertible Note, dated September 16, 2022, between One World Products, Inc. and Dr. John McCabe (incorporated by reference to Exhibit 10.16 of the Form 10-Q filed with the Securities and Exchange Commission by on November 14, 2022) Exhibit 10.16 THIS CONVERTIBLE PROMISSORY NOTE AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED U
November 14, 2022	EX-10.15	Convertible Promissory Note Purchase Agreement, dated September 16, 2022, between the Company and Dr. John McCabe (incorporated by reference to Exhibit 10.15 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission by One World Products, Inc. on November 14, 2022) Exhibit 10.15 ONE WORLD PRODUCTS, INC. CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT THIS CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of September 16, 2022 (the “Effective Date”), is entered into by and among One World Products, Inc., a Nevada corporation (the “Company”), and Dr. John McCabe (“Investor”). RECITALS WHEREAS, the Company has agreed to issue and sell,
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUC
October 4, 2022	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) One World Products, Inc.
October 4, 2022	S-1	As filed with the Securities and Exchange Commission on October 4, 2022 As filed with the Securities and Exchange Commission on October 4, 2022 Registration No.
September 7, 2022	EX-10.3	Registration Rights Agreement, dated September 1, 2022, between the Company and Tysadco Partners, LLC (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 7, 2022) Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of September 1, 2022, by and between ONE WORLD PRODUCTS, INC., a Nevada corporation (the ?Company?), and TYSADCO PARTNERS, LLC, a Delaware limited liability company (together with it permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined herein shall have the
September 7, 2022	EX-10.2	Securities Purchase Agreement, dated September 1, 2022, between the Company and Tysadco Partners, LLC (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 7, 2022) Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of September 1, 2022, is entered into by and between One World Products, Inc., a Nevada corporation, (the ?Company?), and Tysadco Partners, LLC, a Delaware limited liability company (the ?Buyer?). A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the ex
September 7, 2022	8-K	Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 One World Products, Inc. (Exact name of registrant as specified in charter) Nevada 000-56151 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File
September 7, 2022	EX-10.1	Purchase Agreement, dated September 1, 2022, between the Company and Tysadco Partners, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 7, 2022) Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of September 1, 2022, is entered into by and between ONE WORLD PRODUCTS, INC., a Nevada corporation (the ?Company?), and TYSADCO PARTNERS, LLC, a Delaware limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor,
August 22, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PRODUCTS,
August 15, 2022	NT 10-Q	UNITED STATES SECURITIES ANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES ANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires:April 30, 2025 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-200529 CUSIP NUMBER 68248W 108 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: June 30, 20
August 4, 2022	EX-3.1	Certificate of Amendment to Certificate of Designation of the Series B Preferred Stock of One World Products, Inc., Pursuant to NRS 78.1955, filed with the Secretary of State of the State of Nevada on August 2, 2022. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on August 4, 2022) Exhibit 3.1
August 4, 2022	8-K	Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 One World Products, Inc. (Exact name of registrant as specified in charter) Nevada 000-56151 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PRODUCTS,
May 16, 2022	EX-10.10	Commercial Lease Agreement dated November 26, 2021, between R&B Inversiones S.A.S. and One World Pharma S.A.S. (incorporated by reference to Exhibit 10.10 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 16, 2022) Exhibit 10.10
May 16, 2022	EX-10.11	Residential Lease Agreement dated February 14, 2020, between Grupo Empresarial OIKOS S.A.S. and One World Pharma S.A.S. (incorporated by reference to Exhibit 10.11 of the Form 10-Q filed with the Securities and Exchange Commission by One World Products, Inc. on May 16, 2022) Exhibit 10.11 CONTRACT OF LEASE OF PROPERTIES Page 3 of 9 PART TWO THE LESSOR together with THE LESSEE hereinafter THE PARTIES, we have agreed to enter into this Lease contract, hereinafter THE CONTRACT, which will be governed by the rules that regulate the matter according to the use of the property, especially by the following clauses and taking into account the following: CONSIDERATIONS THE LES
April 15, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PRODUCTS, INC.
April 15, 2022	EX-10.2	Addendum to Commercial Lease dated November 1, 2021, between Ripper Series, LLC and OWP Ventures, Inc. (incorporated by reference to Exhibit 10.2 of the Form 10-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on April 15, 2022). EXHIBIT 10.2
April 15, 2022	EX-10.1	Promissory Note between OWP Ventures, Inc. and Dr. Kenneth Perego, II, dated December 29, 2021 (incorporated by reference to Exhibit 10.1 of the Form 10-K filed with the Securities and Exchange Commission by One World Products, Inc. on April 15, 2022) EXHIBIT 10.1 PROMISSORY NOTE $200,000 Las Vegas, Nevada Maturity: January 1, 2024 December 29, 2021 FOR VALUE RECEIVED, OWP VENTURES, INC., a Delaware corporation (?Borrower?), hereby promises to pay to the order of Dr. Kenneth Perego, II, M.D. (the ?Payee?), with an address at 228 Riverside Lane, Natchez, LA 71456, upon Maturity at January 1, 2024, the principal sum of TWO HUNDRED THOUSAND DOLLAR
April 15, 2022	EX-21.1	Subsidiaries (incorporated by reference to Exhibit 21.1 of the Form 10-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on April 15, 2022). EXHIBIT 21.1 Subsidiaries State/Country of Subsidiary Incorporation OWP Ventures, Inc.(1) Delaware One World Pharma, S.A.S.(2) Bogot? Colombia Colombian Hope, S.A.S.(2) Bogot? Colombia Agrobase, S.A.S.(2) Bogot? Colombia (1)Wholly-owned subsidiary of One World Pharma, Inc. subsequent to merger on February 21, 2019 (2)Wholly-owned subsidiary of OWP Ventures, Inc.
April 1, 2022	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response ......... 2.50 SEC FILE NUMBER 333-200529 CUSIP NUMBER 68248W 108 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: De
February 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 One World Products, Inc. (Exact name of registrant as specified in charter) Nevada 000-56151 61-1744826 (State or other Jurisdiction of Incorporation) (Commission Fi
November 30, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 One World Products, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission F
November 30, 2021	EX-2.1	Agreement and Plan of Merger dated October 11, 2021, between One World Pharma, Inc. and One World Products, Inc. (incorporated by reference to Exhibit 2.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on November 30, 2021) Exhibit 2.1 AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (this ?Agreement?) dated this 11th day of October, 2021, by and between One World Pharma, Inc., a Nevada corporation (?OW Pharma?), and One World Products, Inc., a Nevada corporation and a wholly-owned subsidiary of OW Pharma (?OW Products?), is made with respect to the following facts. RECITALS WHEREAS, OW Pharma is a corp
November 30, 2021	EX-3.1	Articles of Merger Pursuant to NRS 92A.200 as filed with the Nevada Secretary of State on November 23, 2021 (incorporated by reference to Exhibit 2.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on November 30, 2021) Exhibit 3.1
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARM
September 30, 2021	SC 13G	OWPC / One World Pharma Inc / Ellins Craig - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* One World Pharma, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68248W108 (CUSIP Number) June 29, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
September 27, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2021 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission Fi
September 27, 2021	EX-4.3	Common Stock Purchase Warrant to purchase 2,000,000 shares of common stock of One World Pharma, Inc. issued to AJB Capital Investments LLC, dated September 24, 2021 (incorporated by reference to Exhibit 4.3 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on September 27, 2021) Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG
September 27, 2021	EX-4.1	Promissory Note of One World Pharma, Inc. in the principal amount of $750,000 issued to AJB Capital Investments LLC, dated September 24, 2021 (incorporated by reference to Exhibit 4.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on September 27, 2021) Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T
September 27, 2021	EX-4.2	Common Stock Purchase Warrant to purchase 1,500,000 shares of common stock of One World Pharma, Inc. issued to AJB Capital Investments LLC, dated September 24, 2021 (incorporated by reference to Exhibit 4.2 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on September 27, 2021) Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG
September 27, 2021	EX-10.2	Security Agreement, dated September 24, 2021, between One World Pharma, Inc. and AJB Capital Investments LLC (incorporated by reference to Exhibit 10.2 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on September 27, 2021) Exhibit 10.2 SECURITY AGREEMENT This SECURITY AGREEMENT (this ?Agreement?) made and effective as of September 24, 2021, is executed by and between ONE WORLD PHARMA, INC., a Nevada corporation (the ?Company?), and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company (the ?Secured Party?). WHEREAS, pursuant to a Securities Purchase Agreement dated as of the date hereof, between the Com
September 27, 2021	EX-10.1	Securities Purchase Agreement, dated September 24, 2021, between One World Pharma, Inc. and AJB Capital Investments LLC (incorporated by reference to Exhibit 10.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on September 27, 2021) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of September 24, 2021, by and between ONE WORLD PHARMA, INC., a Nevada corporation, with headquarters located at 3471 W. Oquendo Road, Suite 301, Las Vegas, NV 89118 (the ?Company?), and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company, with its address at 4700 Sheridan Stree
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARMA, IN
June 30, 2021	SC 13D	OWPC / One World Pharma Inc / Thomas Isiah III Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ONE WORLD PHARMA, INC. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 68248W108 (CUSIP Number) Isiah L. Thomas III c/o One World Pharma, Inc. 3471 West Oquendo Road, Suite 301 Las Vegas, Nevada 89118 (800) 605-3201
June 3, 2021	EX-10.1	Letter Agreement, dated May 28, 2021, between One World Pharma, Inc. and Vahé Gabriel (incorporated by reference to Exhibit 10.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on June 3, 2021) Exhibit 10.1 One World Pharma, Inc. 3471 W. Oquendo Road, Suite 301 Las Vegas, NV 89118 May 28, 2021 Vah? Gabriel Dear Mr. Gabriel: We are pleased to confirm the terms of your employment with One World Pharma, Inc. (the ?Company?), effective May 28, 2021 (the ?Effective Date?). The details of your employment are as follows: Title; Duties: You will be employed as the Company?s Chief Financial Offic
June 3, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 000-56151 61-1744826 (State or other Jurisdiction (Commission (IRS Employer of Incorporat
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARM
April 15, 2021	EX-4.1	Description of Securities (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form 10-K filed with the Securities and Exchange Commission on April 15, 2021) EXHIBIT 4.1 ONE WORLD PHARMA, INC. DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following is a brief description of the shares of capital stock of One World Pharma, Inc. (the ?Company,? ?we,? ?us,? or ?our?). The brief description is based upon our Articles of Incorporation, including the Certificate of Amendment to our Articles of Incorporation, (as amended, our ?
April 15, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56151 ONE WORLD PHARMA, INC
April 15, 2021	EX-10.14	Form of Demand Note between One World Pharma, Inc. and Isiah L. Thomas, III, dated December 16, 2020 (incorporated by reference to Exhibit 10.14 of the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2021) Exhibit 10.14 DEMAND PROMISSORY NOTE $125,000 Las Vegas, Nevada December 16, 2020 FOR VALUE RECEIVED, OWP VENTURES, INC., a Delaware corporation (?Borrower?), hereby promises to pay to the order of Isiah Thomas (the ?Payee?), with an address at 24 Carol Court, Rye Brook, NY 10573, ON DEMAND, the principal sum of ONE HUNDRED TWENTY-FIVE THOUSAND DOLLARS ($125,000), together with all interest that h
April 2, 2021	NT 10-K	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-200529 CUSIP NUMBER 68248W 108 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio
February 8, 2021	EX-10.1	Securities Purchase Agreement, dated as of February 7, 2021, between the Company and ISIAH International LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 8, 2021) Exhibit 10.1 securities purchase AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), between One World Pharma, Inc., a Nevada corporation (the “Company”), and ISIAH International, LLC (the “Investor”), is made and entered into as of February 7, 2021. RECITALS A. Subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act (as defin
February 8, 2021	EX-3.1	Certificate of Designation of Series B Preferred Stock of the Company dated February 2, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 8, 2021) Exhibit 3.1 CERTIFICATE OF DESIGNATION OF THE SERIES B PREFERRED STOCK OF ONE WORLD PHARMA, INC. Pursuant to Section 78.1995 of the Nevada Revised Statutes RESOLVED, that pursuant to the authority expressly vested in the Board of Directors of the Corporation by the Articles of Incorporation, as amended (the “Articles of Incorporation”), and in accordance with the provisions of Section 78.1955 of t
February 8, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File
January 25, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File
January 25, 2021	EX-10.2	Security Agreement, dated as of January 20, 2021, between One World Pharma, Inc. and AJB Capital Investments LLC (incorporated by reference to Exhibit 10.2 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on January 25, 2021) Exhibit 10.2 SECURITY AGREEMENT This SECURITY AGREEMENT (this “Agreement”) made and effective as of January 20, 2021, is executed by and between ONE WORLD PHARMA, INC., a Nevada corporation (the “Company”), and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company (the “Secured Party”). WHEREAS, pursuant to a Securities Purchase Agreement dated as of the date hereof, between the Compa
January 25, 2021	EX-10.1	Securities Purchase Agreement, dated as of January 20, 2021, between One World Pharma, Inc. and AJB Capital Investments LLC (incorporated by reference to Exhibit 10.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on January 25, 2021) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 20, 2021, by and between ONE WORLD PHARMA, INC., a Nevada corporation, with headquarters located at 3471 W. Oquendo Road, Suite 301, Las Vegas, NV 89118 (the “Company”), and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company, with its address at 4700 Sheridan Street,
January 25, 2021	EX-4.1	Promissory Note of One World Pharma, Inc. in the principal amount of $290,000 issued to AJB Capital Investments LLC, dated January 20, 2021 (incorporated by reference to Exhibit 4.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on January 25, 2021) Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T
November 23, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD P
November 17, 2020	NT 10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-200529 CUSIP NUMBER 68248W 108 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio
August 14, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARMA
June 26, 2020	EX-3.4	Certificate of Designation of Series A Preferred Stock of the Registrant dated June 1, 2020 (incorporated by reference to Exhibit 3.4 of the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on June 26, 2020) Exhibit 3.4 CERTIFICATE OF DESIGNATION OF THE SERIES A PREFERRED STOCK OF ONE WORLD PHARMA, INC. Pursuant to Section 78.1995 of the Nevada Revised Statutes RESOLVED, that pursuant to the authority expressly vested in the Board of Directors of the Corporation by the Articles of Incorporation, as amended (the “Articles of Incorporation”), and in accordance with the provisions of Section 78.1955 of t
June 26, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARM
June 9, 2020	EX-10.2	Letter Agreement between the Company and Isiah L. Thomas, III, dated June 3, 2020 (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2020) Exhibit 10.2 One World Pharma, Inc. 3471 W. Oquendo Road, Suite 301 Las Vegas, NV 89118 June 3, 2020 Isiah L. Thomas III Dear Mr. Thomas: We are pleased to confirm the terms of your employment with One World Pharma, Inc. (the “Company”), effective June 3, 2020. The details of your employment are as follows: Title; Duties: You will be employed as the Chief Executive Officer performing such duties a
June 9, 2020	EX-10.1	Separation and Release Agreement between One World Pharma, Inc. and Craig Ellins, dated June 3, 2020 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on June 9, 2020) Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Agreement (this “Agreement”) is made as of June 3, 2020, by and between ONE WORLD PHARMA, INC., a Nevada corporation (the “Company”), and CRAIG ELLINS (“Ellins”). RECITALS WHEREAS, Ellins is currently employed as the Company’s Chief Executive Officer and Chief Financial Officer, serves as a director of the Company, and serves as a director and off
June 9, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File Num
May 29, 2020	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARMA, IN
May 29, 2020	EX-4.1	Description of Securities (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form 10-K filed with the Securities and Exchange Commission on May 29, 2020) EXHIBIT 4.1 ONE WORLD PHARMA, INC. DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following is a brief description of shares of common stock (“common stock”) of One World Pharma, Inc. (the “Company,” “we,” “us,” or “our”). The brief description is based upon our Articles of Incorporation, including the Certificate of Amendment to our Articles of Incorporation, (as am
May 15, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):May 15, 2020 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File Numb
May 15, 2020	NT 10-K/A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25/A NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-200529 CUSIP NUMBER 68248W 108 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Per
May 8, 2020	EX-10.1	Promissory Note dated May 4, 2020, made by OWP Ventures, Inc. in favor of Customers Bank (incorporated by reference to Exhibit 10.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on May 8, 2020) Exhibit 10.1
May 8, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File Numb
March 31, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File N
March 31, 2020	NT 10-K	OWPC / One World Pharma, Inc. NT 10-K - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-200529 CUSIP NUMBER 68248W 108 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio
March 3, 2020	8-A12G	OWPC / One World Pharma, Inc. 8-A12G - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 One World Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 61-1744826 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Numb
February 25, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission Fil
February 25, 2020	EX-10.3	Form of Option Agreement for grants under the 2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020) EX-10.3 5 ex10-3.htm Exhibit 10.3 ONE WORLD PHARMA, INC. 2019 Stock Incentive Plan Option Agreement Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, One World Pharma, Inc. (the “Company”) has granted you an option under its 2019 Stock Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at th
February 25, 2020	EX-14.1	One World Pharma, Inc. Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020) Exhibit 14.1 One World pharma, Inc. Code of Business Conduct and Ethics Introduction We are committed to maintaining the highest standards of business conduct and ethics. This Code of Business Conduct and Ethics (the “Code”) reflects the business practices and principles of behavior that support this commitment, and is intended to qualify as a “code of ethics” within the meaning of the Sarbanes-Ox
February 25, 2020	EX-3.1	Certificate of Amendment to Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020) Exhibit 3.1
February 25, 2020	EX-10.1	One World Pharma, Inc. 2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020) EX-10.1 3 ex10-1.htm Exhibit 10.1 ONE WORLD PHARMA, INC. 2019 Stock Incentive Plan 1. General. (a) Eligible Award Recipients. The persons eligible to receive Awards are Employees, Directors and Consultants. (b) Available Awards. The Plan provides for the grant of the following Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights (iv) Restricted Stoc
February 25, 2020	EX-10.2	Form of Stock Option Grant Notice for grants under the 2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2020) EX-10.2 4 ex10-2.htm Exhibit 10.2 One World Pharma, Inc. Stock Option Grant Notice (2019 Stock Incentive Plan) One World Pharma, Inc. (the “Company”), pursuant to its 2019 Stock Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth he
December 10, 2019	EX-10.1	Share Purchase Agreement between OWP Ventures, Inc., Engineering Consulting S.A.S. and Lina María Isaza Díaz, dated September 26, 2019 Share Purchase Agreement This Share Purchase Agreement (the “Agreement”) is made by and between: (i) OWP Ventures, Inc.
December 10, 2019	EX-99.1	Colombia’s FEDECORE and One World Pharma Join Forces to Develop Large Scale Hemp Projects Benefitting Small Farmers Joint Venture Expected to Provide Significant Revenue Opportunities & Aligns With Company’s Humanitarian Efforts Colombia’s FEDECORE and One World Pharma Join Forces to Develop Large Scale Hemp Projects Benefitting Small Farmers Joint Venture Expected to Provide Significant Revenue Opportunities & Aligns With Company’s Humanitarian Efforts LAS VEGAS, NV (December 9, 2019) – One World Pharma Inc.
December 10, 2019	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2019 One World Pharma, Inc. (Exact name of registrant as specified in charter) Nevada 333-200529 61-1744826 (State or other Jurisdiction of Incorporation) (Commission File
November 14, 2019	10-Q	OWPC / One World Pharma, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD P
October 10, 2019	424B3	PROSPECTUS October 8, 2019 ONE WORLD PHARMA, INC. 9,824,359 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-233735 PROSPECTUS October 8, 2019 ONE WORLD PHARMA, INC. 9,824,359 Shares of Common Stock This prospectus relates to the offering and resale by the selling shareholders identified herein of up to 9,824,359. We will not receive any proceeds from the sale of these shares by the selling shareholders. The selling shareholders may sell all or a port
October 4, 2019	CORRESP	OWPC / One World Pharma, Inc. CORRESP - - ONE WORLD PHARMA, INC. 3471 West Oquendo Road, Suite 301 Las Vegas NV 89118 October 4, 2019 Via Edgar U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, DC 20549 Attention: Donald Field Justin Dobbie Re: One World Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-233735 Request for Accelerat
October 3, 2019	S-1/A	OWPC / One World Pharma, Inc. S-1/A - - As filed with the Securities and Exchange Commission on October 3, 2019 Registration No.
October 3, 2019	CORRESP	OWPC / One World Pharma, Inc. CORRESP - - 101 Park Avenue Suite 1700 New York, NY 10178 Tel (212) 878-7900 Fax (212) 692-0940 www.
September 12, 2019	S-1	OWPC / One World Pharma, Inc. S-1 - Registration Statement - As filed with the Securities and Exchange Commission on September 12, 2019 Registration No.
September 12, 2019	EX-10.12	Convertible Promissory Note dated July 22, 2019, made by One World Pharma, Inc. in favor of CSW Ventures, LP in the principal amount of $207,332 Exhibit 10.12 THIS CONVERTIBLE PROMISSORY NOTE AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED U
August 13, 2019	10-Q	OWPC / One World Pharma, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARMA
July 12, 2019	8-K/A	Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Change in Shell Company Status UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 3 CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 ONE WORLD PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 333-200529 61-1744826 (State or other jurisdiction of
July 12, 2019	EX-99.3	One World Pharma, Inc. and OWP Ventures, Inc. Pro Forma Financial Information For the Year Ended December 31, 2018 Exhibit 99.3 One World Pharma, Inc. and OWP Ventures, Inc. Pro Forma Financial Information (Unaudited) For the Year Ended December 31, 2018 On February 21, 2019, One World Pharma, Inc. (“the Company”) entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., our wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”), which is the parent company of One World Pharma, S
July 12, 2019	EX-99.2	OWP VENTURES, INC. AUDITED FINANCIAL STATEMENTS For the Year Ended December 31, 2018 TABLE OF CONTENTS Exhibit 99.2 OWP VENTURES, INC. AUDITED FINANCIAL STATEMENTS For the Year Ended December 31, 2018 TABLE OF CONTENTS Report of Independent Registered Public Accounting Firm F-1 Consolidated Balance Sheet as of December 31, 2018 F-2 Consolidated Statement of Operations and Comprehensive Income for the period from inception (March 27, 2018) through December 31, 2018 F-3 Consolidated Statement of Stoc
July 12, 2019	CORRESP	OWPC / One World Pharma, Inc. CORRESP - - 101 Park Avenue Suite 1700 New York, NY 10178 Tel (212) 878-7900 Fax (212) 692-0940 www.
June 28, 2019	CORRESP	OWPC / One World Pharma, Inc. CORRESP - - 101 Park Avenue Suite 1700 New York, NY 10178 Tel (212) 878-7900 Fax (212) 692-0940 www.
June 13, 2019	EX-99.2	OWP VENTURES, INC. AUDITED FINANCIAL STATEMENTS For the Year Ended December 31, 2018 TABLE OF CONTENTS Exhibit 99.2 OWP VENTURES, INC. AUDITED FINANCIAL STATEMENTS For the Year Ended December 31, 2018 TABLE OF CONTENTS Report of Independent Registered Public Accounting Firm F-1 Consolidated Balance Sheet as of December 31, 2018 F-2 Consolidated Statement of Operations and Comprehensive Income for the period from inception (March 27, 2018) through December 31, 2018 F-3 Consolidated Statement of Stoc
June 13, 2019	EX-10.11	Purchase Agreement, dated as of June 4, 2019, between One World Pharma S.A.S. and Wala Popayan (incorporated by reference to Exhibit 10.11 of the Registrant’s Current Report on Form 8-K/A filed with the Securities and Exchange Commission on June 13, 2019).
June 13, 2019	EX-10.10	Purchase Agreement, dated as of May 18, 2019, between One World Pharma S.A.S. and Pharma Indigena Misak Manasr S.A.S. (incorporated by reference to Exhibit 10.10 of the Registrant’s Current Report on Form 8-K/A filed with the Securities and Exchange Commission on June 13, 2019).
June 13, 2019	EX-99.3	One World Pharma, Inc. and OWP Ventures, Inc. Pro Forma Financial Information For the Year Ended December 31, 2018 Exhibit 99.3 One World Pharma, Inc. and OWP Ventures, Inc. Pro Forma Financial Information (Unaudited) For the Year Ended December 31, 2018 On February 21, 2019, One World Pharma, Inc. (“the Company”) entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., our wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”), which is the parent company of One World Pharma, S
June 13, 2019	8-K/A	Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Change in Shell Company Status 8-K/A 1 form8-ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 2 CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 ONE WORLD PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 333-200529 61-1744826 (State or o
June 13, 2019	CORRESP	OWPC / One World Pharma, Inc. CORRESP - - 101 Park Avenue Suite 1700 New York, NY 10178 Tel (212) 878-7900 Fax (212) 692-0940 www.
May 29, 2019	10-Q	OWPC / One World Pharma, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARM
May 16, 2019	NT 10-Q	OWPC / One World Pharma, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-200529 CUSIP NUMBER 68248W 108 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Perio
April 30, 2019	EX-99.3	One World Pharma, Inc. and OWP Ventures, Inc. Pro Forma Financial Information For the Year Ended December 31, 2018 Exhibit 99.3 One World Pharma, Inc. and OWP Ventures, Inc. Pro Forma Financial Information (Unaudited) For the Year Ended December 31, 2018 On February 21, 2019, One World Pharma, Inc. (“the Company”) entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., our wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”), which is the parent company of One World Pharma, S
April 30, 2019	8-K/A	Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Change in Shell Company Status UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 ONE WORLD PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 333-200529 61-1744826 (State or other jurisdiction of
April 30, 2019	EX-99.2	OWP VENTURES, INC. AUDITED FINANCIAL STATEMENTS For the Year Ended December 31, 2018 TABLE OF CONTENTS Exhibit 99.2 OWP VENTURES, INC. AUDITED FINANCIAL STATEMENTS For the Year Ended December 31, 2018 TABLE OF CONTENTS Report of Independent Registered Public Accounting Firm F-1 Consolidated Balance Sheet as of December 31, 2018 F-2 Consolidated Statement of Operations and Comprehensive Income for the period from inception (March 27, 2018) through December 31, 2018 F-3 Consolidated Statement of Stoc
April 1, 2019	10-K	OWPC / One World Pharma, Inc. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-200529 ONE WORLD PHARMA, INC. (
February 25, 2019	EX-10.1	Convertible Note in the Principal Amount of $300,000 issued by OWP Ventures, Inc. to CSW Investors, LP (incorporated by reference to Exhibit 10.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UN
February 25, 2019	8-K	Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Change in Shell Company Status UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 ONE WORLD PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 333-200529 61-1744826 (State or other jurisdiction of incorporation or o
February 25, 2019	EX-10.5	Form of Demand Promissory Note issued by OWP Ventures, Inc. to Craig Ellins (incorporated by reference to Exhibit 10.5 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.5 DEMAND PROMISSORY NOTE $ 10,000.00 Las Vegas, Nevada May 3, 2018 FOR VALUE RECEIVED, OWP VENTURES, INC., a Delaware corporation (“Borrower”), hereby promises to pay to the order of Craig Ellins (the “Payee”), with an address at 6500 Bullring Lane, Las Vegas NV 89130 , ON DEMAND, the principal sum of TEN THOUSAND DOLLARS ($10,000), together with all interest that has accrued thereon fr
February 25, 2019	EX-16.1	Letter on Change in Certifying Accountant dated February 22, 2019 (incorporated by reference to Exhibit 2.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 25, 2019). Exhibit 16.1 February 22, 2019 U.S. Securities and Exchange Commission Office of the Chief Accountant 100F Street Northeast Washington, DC 20549-2000 RE: One World Pharma, Inc. File No. 333-200529 Dear Sir or Madam: We have read Item 4.01 of Form 8-K dated February 22, 2019 of One World Pharma, Inc. (“the Registrant”) and are in agreement with the statements contained therein as it pertains to our
February 25, 2019	EX-21.1	Subsidiaries (incorporated by reference to Exhibit 21.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) EX-21.1 13 f8k022119ex21-1oneworld.htm SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 Subsidiaries State/Country of Subsidiary Incorporation OWP Ventures, Inc.(1) Delaware One World Pharma, S.A.S.(2) Bogotá Colombia (1) Wholly-owned subsidiary of One World Pharma, Inc. subsequent to merger on February 21, 2019 (2) Wholly-owned subsidiary of OWP Ventures, Inc.
February 25, 2019	EX-2.1	Agreement and Plan of Merger dated February 21, 2019, among the Registrant, OWP Merger Subsidiary Inc. and OWP Ventures, Inc. (incorporated by reference to Exhibit 2.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ONE WORLD PHARMA, INC., OWP MERGER SUBSIDIARY, INC. and OWP VENTURES, INC. February 21, 2019 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II THE MERGER 3 Section 2.1 Merger 3 Section 2.2 Effective Time 3 Section 2.3 Certificate of Incorporation; By-laws; Directors and Officers 3 Section 2.4 Effects of the Merger 4 Section 2.5 Closing
February 25, 2019	EX-10.9	Convertible Promissory Note Purchase between OWP Ventures, Inc. and The Sanguine Group, LLC (incorporated by reference to Exhibit 10.9 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.9 THIS CONVERTIBLE PROMISSORY NOTE AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UN
February 25, 2019	EX-10.7	Service Agreement dated February 19, 2019, between One World Pharma, Inc. and Integrity Media (incorporated by reference to Exhibit 10.7 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.7 Service Agreement Company to be covered: One World Pharma, Inc. This Service Agreement (the “Agreement”) is by and between Integrity Media, Inc., a Nevada corporation (“IMI”), and One World Pharma, Inc. (OWP), a Nevada corporation (the “COMPANY”). This Agreement is made effective as of February 18, 2019 (the “Effective Date”). IMI and the COMPANY are referred to herein individually as
February 25, 2019	EX-10.2	Consulting Agreement between OWP Ventures, Inc. and Bruce Raben dated February 8, 2019 (incorporated by reference to Exhibit 10.2 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is made as of February 8, 2019 between OWP Ventures, Inc., a Delaware corporation (“Company”), and Bruce Raben (“Consultant”, and together with Company, the “Parties”). WHEREAS, Company is desirous of obtaining the services of Consultant, and Consultant is desirous of offering its consulting services to the Company, on the t
February 25, 2019	EX-10.4	Commercial Lease dated October 16, 2018, between Ripper Series, LLC and OWP Ventures, Inc. (incorporated by reference to Exhibit 10.4 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.4
February 25, 2019	EX-99.2	OWP VENTURES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS Exhibit 99.2 OWP VENTURES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2018 2017 (Unaudited) Assets Current assets: Cash $ 115,094 $ 4,739 Note receivable 50,000 - Other current assets 153,288 4,165 Total current assets 318,382 8,904 Fixed assets, net 253,398 - Total Assets $ 571,780 $ 8,904 Liabilities and Stockholders’ (Deficit) Current liabilities: Accounts payable $ 4
February 25, 2019	EX-99.3	OWP VENTURES, INC. / PUNTO GROUP, CORP. PRO FORMA CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION Exhibit 99.3 OWP VENTURES, INC. / PUNTO GROUP, CORP. PRO FORMA CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION (Unaudited) As of September 30, 2018 OWP Punto Group, Pro Forma Ventures, Inc. Corp. Elimination Combined ASSETS Current assets $ 318,382 $ - $ - $ 318,382 Other assets 253,398 - - 253,398 Total assets $ 571,780 $ - $ - $ 571,780 LIABILITIES AND EQUITY (DEFICIT) Current liabilities $ 282,4
February 25, 2019	EX-10.6	Amended and Restated Promissory Note in the principal amount of $307,141, dated February 13, 2019, issued by OWP Ventures, Inc. to Craig Ellins (incorporated by reference to Exhibit 10.6 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.6 AMENDED AND RESTATED PROMISSORY NOTE $307,140.92 Las Vegas, Nevada February 13, 2019 FOR VALUE RECEIVED, OWP VENTURES, INC., a Delaware corporation (“Borrower”), hereby promises to pay to the order of CRAIG ELLINS (“Payee”), with an address at 6500 Bullring Lane, Las Vegas, Nevada 89130, in lawful money of the United States of America, on the earlier of (i) a Qualified Financing (as d
February 25, 2019	EX-10.3	Commercial Lease dated December 2, 2018, between Larry R. Haupert dba Rexco and One World Pharma S.A.S. (incorporated by reference to Exhibit 10.3 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.3 English Translation From Spanish Original GALINDO CUBIDES, LAWYERS Building World Trade Center tower A Street 100 No. 8A 37 of 207 Telephone number 218 39 64 - 218 39 84 email [email protected] Bogota Colombia Leasing contract office 1903 connected towers two - bogota d.c. Place and date of contract: Bogota D.C. October 25 of 2018 Among the undersigned HERNANDO GALINDO C
February 25, 2019	EX-10.8	Convertible Promissory Note Purchase Agreement between OWP Ventures, Inc. and The Sanguine Group, LLC (incorporated by reference to Exhibit 10.8 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019) Exhibit 10.8 OWP VENTURES, INC. CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT THIS CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of January 14, 2019 (the “Effective Date”), is entered into by and among OWP Ventures, Inc., a Delaware corporation (the “Company”), and the undersigned investors (individually an “Investor” and collectively, the “Investors”). RECITALS WHER
February 25, 2019	EX-99.1	ONE WORLD PHARMA SAS AUDITED FINANCIAL STATEMENTS For the Year Ended December 31, 2017 TABLE OF CONTENTS Exhibit 99.1 ONE WORLD PHARMA SAS AUDITED FINANCIAL STATEMENTS For the Year Ended December 31, 2017 TABLE OF CONTENTS Report of Independent Registered Public Accounting Firm 1 Balance Sheet as of December 31, 2017 2 Statement of Operations for the period from inception (July 14, 2017) through December 31, 2017 3 Statement of Stockholders’ Equity (Deficit) for the year ended December 31, 2017 4 Sta
January 8, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 PUNTO GROUP, CORP. (Exact name of registrant as specified in its charter) Nevada 333-200529 61-1744826 (State or other jurisdiction of incorporation or organiz
January 8, 2019	EX-3.1	Certificate of Amendment to Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 8, 2019) Exhibit 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) USE BLACK INK ONLY – DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 -
December 6, 2018	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2018 PUNTO GROUP, CORP. (Exact name of registrant as specified in its charter) Nevada 333-200529 61-1744826 (State or other jurisdiction of incorporation or organ
November 14, 2018	10-Q	PNTT / Punto Group, Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP
August 14, 2018	10-Q	PNTT / Punto Group, Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP, COR
May 21, 2018	10-Q	PNTT / Punto Group, Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP, CO
May 16, 2018	NT 10-Q	PNTT / Punto Group, Corp. NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-200529 CUSIP NUMBER: 746040104 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra
April 4, 2018	10-K	PNTT / Punto Group, Corp. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 333-200529 Punto Group, Corp. Nevada 61-174
April 2, 2018	NT 10-K	PNTT / Punto Group, Corp. NOTIFICATION OF LATE FILING SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-200529 CUSIP NUMBER: 746040104 (Check One): x Form 10-K oForm 20-F o Form 11-K o Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: December 31, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.
November 14, 2017	10-Q	PNTT / Punto Group, Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP
August 21, 2017	10-Q	PNTT / Punto Group, Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP, COR
August 15, 2017	NT 10-Q	Punto Group NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-200529 CUSIP NUMBER: 746040104 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Tran
May 22, 2017	10-Q	Punto Group QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP, CO
May 19, 2017	NT 10-Q	Punto Group NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-200529 CUSIP NUMBER: 746040104 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Tra
April 26, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 333-200529 Punto Group, Corp. Nevada 61-17
March 31, 2017	NT 10-K	Punto Group NOTIFICATION OF LATE FILING NT 10-K 1 extf10k2016puntogroup.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-200529 CUSIP NUMBER: 746040104 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2016 ☐ Transition Report on Form 10-K ☐ Tr
November 14, 2016	10-Q	Punto Group QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP
August 15, 2016	10-Q	Punto Group QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP, COR
August 15, 2016	10-Q	Punto Group QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP, COR
May 17, 2016	10-Q	Punto Group QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number: 333-200529 PUNTO GROUP, CO
May 17, 2016	NT 10-Q	Punto Group NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-200529 CUSIP NUMBER: 746040104 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Tra
April 14, 2016	10-K	Punto Group ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from October 1, 2015 to December 31, 2015 Commission File No. 333-200529 Punto Group, Co
March 31, 2016	NT 10-K	Punto Group NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 333-200529 CUSIP NUMBER: 746040104 (Check one): ☒ Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: x Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report
February 18, 2016	EX-16.1	Punto Group Corp. Exhibit No. 16.1 Punto Group Corp. File No. 333-200529 Form 8-K Report Date: February 16, 2016 February 17, 2016 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Gentlemen: On February 17, 2016, this Firm received the final copy of a Current Report on Form 8-K to be filed by Punto Group Corp. (SEC File #333-200529, CIK #0001622244) (?Company?) reporting an Item 4.01 ?
February 18, 2016	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2016 PUNTO GROUP, CORP. (Exact name of registrant as specified in its charter) Nevada 333-200529 61-1744826 (State or other jurisdiction of incorporation or organ
January 12, 2016	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2016 PUNTO GROUP, CORP. (Exact Name of Registrant as Specified in Charter) Nevada 333-200529 61-1744826 (State or Other Jurisdiction of Incorporation) (Commission File Numb
January 12, 2016	SC 14F1	Punto Group SCHEDULE 14F-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(F) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14F-1 THEREUNDER PUNTO GROUP, CORP. (Exact name of registrant as specified in its corporate charter) Nevada 333-200529 61-1744826 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer I
October 22, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 333-200529 Punto Group, Corp. Nevada
August 17, 2015	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Mark One [ X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 333-200529 Punto Group, Corp. Nev
May 29, 2015	424B3	PUNTO GROUP, CORP. 4,000,000 SHARES OF COMMON STOCK $0.02 PER SHARE S-1 Filed Pursuant to Rule 424(b)(3) SEC File No. 333-200529 The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities, nor does it seek an offer to buy these securities in any jurisdictio
May 27, 2015	CORRESP	Punto Group ESP Punto Group, Corp. PUNTO GROUP, CORP. 1810 E. Sahara Ave., Office 216, Las Vegas, NV 89104 Tel: (702) 605-0605 May 27, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Attention: Mr. Ivan Griswold Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-1 (File No. 333-200529) of Punto G
May 18, 2015	S-1/A	Punto Group A S-1 As filed with the Securities and Exchange Commission on May 15 , 2015. Registration No. 333-200529 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Punto Group, Corp. (Exact name of registrant as specified in its charter) Nevada 7372 61-1744826 (State or other jurisdiction of incorporatio
May 15, 2015	CORRESP	Punto Group ESP Title PUNTO GROUP, CORP. 1810 E. Sahara Ave., Office 216, Las Vegas, NV 89104 Tel: (702) 605-0605 May 15, 2015 Mr. Ivan Griswold, United States Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Punto Group, Corp. Amendment No. 4 to Registration Statement on Form S-1 Filed April 17, 2015 File No. 333-200529 Dear Mr. Ivan Griswold: Pursuant to the phone conver
April 17, 2015	S-1/A	Punto Group A S-1 As filed with the Securities and Exchange Commission on April 17 , 2015. Registration No. 333-200529 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Punto Group, Corp. (Exact name of registrant as specified in its charter) Nevada 7372 61-1744826 (State or other jurisdiction of incorporat
April 17, 2015	CORRESP	Punto Group ESP Title PUNTO GROUP, CORP. 1810 E. Sahara Ave., Office 216, Las Vegas, NV 89104 Tel: (702) 605-0605 April 17, 2015 Mr. Ivan Griswold, United States Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Punto Group, Corp. Amendment No. 3 to Registration Statement on Form S-1 Filed March 19, 2015 File No. 333-200529 Dear Mr. Ivan Griswold: Punto Group, Corp. (the ?C
March 19, 2015	S-1/A	Punto Group A S-1 As filed with the Securities and Exchange Commission on March 19 , 2015. Registration No. 333-200529 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Punto Group, Corp. (Exact name of registrant as specified in its charter) Nevada 7372 61-1744826 (State or other jurisdiction of incorporat
March 19, 2015	CORRESP	Punto Group ESP Title PUNTO GROUP, CORP. 1810 E. Sahara Ave., Office 216, Las Vegas, NV 89104 Tel: (702) 605-0605 March 19, 2015 Mr. Ivan Griswold, United States Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Punto Group, Corp. Amendment No. 2 to Registration Statement on Form S-1 Filed February 18, 2015 File No. 333-200529 Dear Mr. Ivan Griswold: Punto Group, Corp. (the
February 18, 2015	CORRESP	OWPC / One World Pharma, Inc. CORRESP - - Title PUNTO GROUP, CORP. 1810 E. Sahara Ave., Office 216, Las Vegas, NV 89104 Tel: (702) 605-0605 February 18, 2015 Mr. Ivan Griswold, United States Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Punto Group, Corp. Amendment No. 1 to Registration Statement on Form S-1 Filed January 12, 2015 File No. 333-200529 Dear Mr. Ivan Griswold: Punto Group, Corp. (t
February 18, 2015	EX-99.1	PUNTO GROUP, CORP. INVESTMENT CONFIRMATION To: Exhibit 99.1 PUNTO GROUP, CORP. INVESTMENT CONFIRMATION The undersigned, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase shares of the common stock of Punto Group, Corp., a Nevada corporation (the "Company"), for a purchase price of $, or $0.02 per share. Simultaneous with the execution and delivery of this confirmation to the Company, the undersigned is
February 18, 2015	S-1/A	OWPC / One World Pharma, Inc. S-1/A - - FORM S-1/A S-1 As filed with the Securities and Exchange Commission on February 18 , 2015. Registration No. 333-200529 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Punto Group, Corp. (Exact name of registrant as specified in its charter) Nevada 7372 61-1744826 (State or other jurisdiction of incorpo
January 12, 2015	EX-99.1	PUNTO GROUP, CORP. INVESTMENT CONFIRMATION To: Exhibit 99.1 PUNTO GROUP, CORP. INVESTMENT CONFIRMATION The undersigned, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase shares of the common stock of Punto Group, Corp., a Nevada corporation (the "Company"), for a purchase price of $, or $0.02 per share. Simultaneous with the execution and delivery of this confirmation to the Company, the undersigned is
January 12, 2015	S-1/A	OWPC / One World Pharma, Inc. S-1/A - - S-1 As filed with the Securities and Exchange Commission on January 9, 2015 . Registration No. 333- 200529 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No.1 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Punto Group, Corp. (Exact name of registrant as specified in its charter) Nevada 7372 61-1744826 (State or other jurisdiction of incorpora
January 9, 2015	CORRESP	OWPC / One World Pharma, Inc. CORRESP - - 2015 PUNTO GROUP, CORP. 1810 E. Sahara Ave., Office 216, Las Vegas, NV 89104 Tel: (702) 605-0605 January 9, 2014 Mr. Ivan Griswold, United States Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Punto Group, Corp. Registration Statement on Form S-1 Filed November 24, 2014 File No. 333-200529 Dear Mr. Ivan Griswold: Punto Group, Corp. (the “Company”) herewit
November 24, 2014	EX-3.1	Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 24, 2014) exhibit Exhibit 3.1
November 24, 2014	S-1	OWPC / One World Pharma, Inc. S-1 - Registration Statement - FORM S-1 S-1 As filed with the Securities and Exchange Commission on November 24, 2014. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Punto Group, Corp. (Exact name of registrant as specified in its charter) Nevada 7372 61-1744826 (State or other jurisdiction of incorporation or organization) (P
November 24, 2014	EX-3.2	Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 24, 2014) exhibit Exhibit 3.2 BYLAWS OF PUNTO GROUP, CORP. (a Nevada corporation) ARTICLE I Meetings of Stockholders and Other Stockholder Matters SECTION 1. Annual Meeting. An annual meeting of the stockholders of Punto Group, Corp., a Nevada corporation (hereinafter, the “Corporation”) shall be held for the election of directors and for the transaction of such other proper business at such time, date and

OWPC / One World Products, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)